An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Trial Status: active
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the
safety of volrustomig in combination with chemotherapy compared with pembrolizumab in
combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 < 50%.
Inclusion Criteria
Histologically or cytologically documented squamous or non-squamous NSCLC.
Stage IV NSCLC (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology 2016), not amenable to curative surgery or radiation.
Absence of sensitizing EGFR mutations and ALK and ROS1 rearrangements.
Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted first-line therapies. Key
Exclusion Criteria
Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant. Rare subtypes are excluded.
Spinal cord compression.
Symptomatic brain metastases. Brain metastases may be treated or untreated, but participants must be asymptomatic and off steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of brain radiotherapy and study enrollment.
History of another primary malignancy except for:
Malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence.
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
Adequately treated carcinoma in situ without evidence of disease.
As judged by the investigator, any condition that would interfere with evaluation of the study intervention or interpretation of participant safety or study results.
Additional locations may be listed on ClinicalTrials.gov for NCT05984277.